Is AstraZeneca/Sanofi Library Exchange Open Innovation's Future?

Taking collaboration to a new level within Big Pharma, AstraZeneca PLC and Sanofi SA have agreed to share 210,000 of their proprietary chemical compounds from their respective libraries in a bid to increase the number of leads for new medicines. No money will change hands, both companies will be free to use the compounds without restriction, and any profits resulting from one of the two's successful development of a drug using the library would not be shared.

More from Anticancer

More from Therapy Areas